Iran is a leader in Phase III clinical trials in women�s health: analysis

INSUBCONTINENT EXCLUSIVE:
other country.Active trials per year for Iran ranged from 58 in 2015 to 115 in 2019, with the next highest trials per year for a country
been withdrawn, terminated, or suspended
Active trials per year for Iran ranged from 58 in 2015 to 115 in 2019, with the next highest trials per year for a country being the United
trials than any other country in most indications.However, the overall data is possibly skewed by an overwhelming lead in Phase III trials
is difficult to diagnose, generally under-researched, and can lead to infertility or other serious health conditions such as coronary heart
disease.Many Iranian trial sites have focused on the effect of various supplements on those with PCOS
In other indications such as pre-eclampsia and endometriosis, while not as large a majority, it is still undoubtedly Iran that leads the
area of research.At present, the lack of female doctors has caused issues with the development of the program, but nevertheless, there are
several female-only hospitals operational in Iran, mostly attached to universities and medical schools.One of these hospitals, the Arash
held in the last week of the Iranian calendar month of Mehr (ending October 22).MG